Innoviva, Inc. Files 8-K on Financials
Ticker: INVA · Form: 8-K · Filed: May 8, 2024 · CIK: 1080014
| Field | Detail |
|---|---|
| Company | Innoviva, INC. (INVA) |
| Form Type | 8-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Innoviva dropped its 8-K, check the financials.
AI Summary
Innoviva, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1350 Old Bayshore Highway, Suite 400, Burlingame, California.
Why It Matters
This 8-K filing provides investors with crucial updates on Innoviva's financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant risks.
Key Players & Entities
- Innoviva, Inc. (company) — Registrant
- May 8, 2024 (date) — Date of earliest event reported
- 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010 (address) — Principal executive offices
- 650-238-9600 (phone_number) — Business phone number
FAQ
What specific financial information is being reported in this 8-K?
This 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the excerpt.
When was this 8-K report filed?
The report was filed on May 8, 2024.
What is the primary business of Innoviva, Inc. according to the filing?
The filing lists Innoviva, Inc.'s Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Innoviva, Inc.'s principal executive offices located?
Innoviva, Inc.'s principal executive offices are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010.
What is the Commission File Number for Innoviva, Inc.?
Innoviva, Inc.'s Commission File Number is 000-30319.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-05-08 16:44:50
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share INVA The Nasdaq Stock Mar
Filing Documents
- tm2413603d1_8k.htm (8-K) — 24KB
- tm2413603d1_ex99-1.htm (EX-99.1) — 109KB
- tm2413609d1_ex99-1img01.jpg (GRAPHIC) — 3KB
- 0001104659-24-058747.txt ( ) — 320KB
- inva-20240508.xsd (EX-101.SCH) — 3KB
- inva-20240508_lab.xml (EX-101.LAB) — 33KB
- inva-20240508_pre.xml (EX-101.PRE) — 22KB
- tm2413603d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On May 8, 2024, Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated May 8, 2024 104 Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document) - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INNOVIVA, INC. Date: May 8, 2024 By: /s/ Pavel Raifeld Pavel Raifeld Chief Executive Officer - 3 -